# Chat Transcript — AKT/Melanoma Silencing Paper Analysis (PMID 37931033)

Full conversation covering the deep-dive analysis of Parkman et al., "Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression," Mol Cancer Ther 2024. Compiled from the PATHAI session transcript. Ends where the conversation pivots to building a separate, fictionalized Project Planck benchmark prompt (inspired by this analysis but not itself part of the paper discussion).

---

**User:** [Asked to check whether pharmacological AKT inhibitors were tested at doses adequate relative to their IC50s, and to verify compound identities/mechanisms against primary pharmacology sources rather than the paper's own labels.]

**Assistant:** Verified MK2206 (allosteric AKT inhibitor, IC50 AKT1=8nM/AKT2=12nM/AKT3=65nM) and GDC-0068/ipatasertib (ATP-competitive AKT inhibitor, IC50 AKT1=5nM/AKT2=18nM/AKT3=8nM) against primary pharmacology sources. At the doses tested (MK2206 2.5μM, GDC-0068 1μM), both were 38-313x each compound's own IC50 across all three paralogs — confirming dose adequacy, meaning the null proliferation result seen in most of the 6 cell lines tested is usable evidence, not an artifact of under-dosing.

**User:** [Asked for the drug info to be compiled into a reference table, then a properly rendered table (not plain markdown), and confirmed it should be kept as a durable, reusable cross-paper reference — "This table is a point of reference for future."]

**Assistant:** Built `drug_info_table.md` and `drug_comparison_table.md`, then rendered a proper visual table as `drug_table.html`/`drug_table.pdf` (verified via pdftoppm + image read) covering MK2206, GDC-0068, GDC-0941 (pan-Class I PI3K inhibitor, IC50 p110α=3nM/p110β=33nM/p110γ=75nM/p110δ=3nM), and INY-03-041 (AKT PROTAC/degrader — GDC-0068 conjugated to a CRBN recruiter, dual kinase-inhibition + degradation mechanism, ~77% total AKT reduction at 1μM vs ~89% for siAKT1-3).

**User:** "OK> Lets go back to the columns and the paper read we were doing."

**Assistant:** Returned to building `evidence_training_schema.md`/`evidence_training_examples.md`, adding Target engagement/isoform coverage, Dose tested vs. IC50, Outcome (this evidence alone), Assay/Method, and Endpoint columns, then filled Row 1 (null result, 4/6 cell lines: A375, WM793, MTG001, MTG004) and Row 1b (partial effect, 2/6 cell lines: HT144, SK-MEL28) from Supplementary Figure S1 — the pharmacological inhibition data.

**User:** "Lets do the siRNA. Lets use the same columns we used and see if they fit. OK? So go ahead and propose the next steps."

**Assistant:** Proposed reading Figure 1 (siAKT1-3 knockdown) directly, checking the actual data (not just captions), re-citing relevant rubric sections, and drafting one row at a time.

**User:** "Can you actually extract figure panels and show me on the side for each figure you want to use or analyse?"

**Assistant:** Rendered Figure 1 (page 21 of the paper PDF) and cropped individual panels (A, B, C, D) to display inline, saved into `PMIDS/PMID 37931033/figure1_panels/`.

**User:** [Asked for the actual conclusion from each panel, correlated to the figure.]

**Assistant:** Walked through Panel A (confluence assay, 6 cell lines, siCtrl + 7 siRNA combinations — triple knockdown siAKT1+2+3 flatlines near 0% in all 6 lines, p<0.0001 in every line), Panel B (Western blot confirming knockdown specificity, A375 only), Panel C (P-AKT S473 and total AKT loss under triple knockdown, rescued by WT mouse Akt1), Panel D (cell death assay, Red Image Mean, A375 only — siAKT1-3 death comparable to staurosporine, rescued by WT Akt1).

**User:** "Lay out the 3 sub parts" [of the proliferation claim]

**Assistant:** Split into three claims per rubric §2's compound-claim rule: (1) simultaneous triple knockdown — complete inhibition of proliferation, all 6 lines, no exceptions; (2) single-paralog knockdown alone — no effect, any paralog, all 6 lines; (3) pairwise knockdown — siAKT1+3 specifically shows effect in 3/6 lines (HT144, SK-MEL28, MTG004), no effect in the other 3 or in the other pairwise combos (siAKT1+2, siAKT2+3).

**User:** [Corrected: Claim wording should not bundle cause and effect together — asked to reword as association, not causation, since Evidence grade/Confidence are what establish causal strength, not the Claim field itself.]

**Assistant:** Reworded all three sub-part claims to "is associated with," dropping causal verbs like "causes."

**User:** "Sub-part 2 -- you can still affect growth with siRNA of 1 form or just a 2 siRNA combo, in other cases in literature. So how would you tackle that?"

**Assistant:** Scoped each sub-part's Claim explicitly to "in this study's 6 melanoma cell lines," and added Contradicting evidence notes: sub-part 2 flagged against unstudied outside literature; sub-part 3 flagged as cell-line-dependent even within this same paper's own dataset (same siAKT1+3 knockdown gives opposite results depending on cell line).

**User:** "Which figure is that? Use top right/left, middle r/l, bottom r/l....and redescribe." [for sub-part 1, then 2, then 3]

**Assistant:** Mapped Panel A's 3×2 grid by position (top-left A375, top-right HT144, middle-left SK-MEL28, middle-right WM793, bottom-left MTG001, bottom-right MTG004) and redescribed each sub-part's pattern position-by-position.

**User:** "Your conclusion is OK, except for the fact that you assume all genotype differences but only have access to one PTEN-/-. Agreed?"

**Assistant:** Agreed — corrected the sub-part 3 conclusion to state that the only annotated genotype difference available (WM793's Pten-/- status) doesn't explain the effect/no-effect split (WM793 falls in the no-effect group), rather than claiming "no genetic explanation exists" broadly — the latter overstated what the figure could actually show.

**User:** "But how do you know the knockdowns actually worked??"

**Assistant:** Pulled up Panel B (Western blot, A375 only — siAKT1 and siAKT2 each cross-checked against both AKT1/AKT2 antibodies; siAKT3 blot shows only the AKT3 band, no cross-check).

**User:** "There is something about the three knockdowns that is somewhat interesting in panel 1B. Can you see it?" ... "Yes, and also the response of AKT2 to knockdown. See that?"

**Assistant:** Identified the asymmetric cross-reactivity check (siAKT1/siAKT2 mutually cross-checked, siAKT3 not) and the AKT2 knockdown-kinetics lag (AKT2 band still strong at 18h, fully gone only by 24h, vs. AKT1/AKT3 already reduced at 18h).

**User:** "This may explain why AKT1 and 3 together have an effect compared to when AKT2 is used in combination in the 3 of 6 lines where 1+3 show effect. Agree?"

**Assistant:** Agreed as a plausible, unverified hypothesis: siAKT1+3 excludes AKT2 (the slower-kinetics paralog), so both targeted paralogs are fully gone early, leaving AKT2 as the sole compensator from the start; siAKT1+2 and siAKT2+3 each include AKT2 as a target, and if its kinetics lag holds in combination too, that could leave more residual protection during the critical window — explaining why those combos show no effect anywhere. Flagged explicitly as unconfirmed (Panel B only shows AKT2 kinetics for the single knockdown, not the pairwise combinations).

**User:** [Corrected "messy" language — the data is complex, not messy, since the difficulty is in disentangling redundant paralogs, not data quality.] Also established: flag verification gaps (scope, asymmetry, kinetics) and wait for input rather than deciding unilaterally, erring toward over-flagging.

**Assistant:** Saved both corrections to the rubric (§4) and to memory.

**User:** "What is P-PRAS40" ... "You can add this as an additional check... What would be good to have included by the authors is a target that is not canonically downstream of AKT1/2/3. The PI3K-beta signal in the blot suggests there are no non-specific toxic effects."

**Assistant:** Explained P-PRAS40 (a direct AKT substrate, phospho-specific readout of kinase activity, tied to the paper's mTOR-suppression title). Identified PI3Kβ (upstream, not itself an siRNA target) as an implicit orthogonal specificity control against generic knockdown toxicity — distinct from a loading control or a downstream-effector readout. Saved as a rubric addition and memory (`feedback_orthogonal_specificity_control.md`).

**User:** "So they use AKT1, 2 and 3. But the main Figure 1D, they use only AKT1" ... "Then where do you get the AKT2 and AKT3 idea from?"

**Assistant:** Found the source: the paper states mouse AKT1, AKT2, or AKT3 constructs were each co-transfected to test rescue, but only AKT1's result is reported/shown (Figure 1C-D) — yet the text concludes "any one paralog of mouse AKT can compensate for the other two." Searched Supplementary Figures S3-S7 for "rescue," "AKT2," "AKT3" — found no AKT2/AKT3 rescue data anywhere in the paper.

**User:** "So what do you think is going on? Don't theorize -- give me the most likely scenario."

**Assistant:** Most likely: all three were tested, all three worked similarly, and only AKT1 was shown as a representative example (common practice, space limits) — not confirmed, since no underlying data or "data not shown" clause exists to verify it.

**User:** "So from a siRNA studies... AKT1, 2, 3... what can we extrapolate?"

**Assistant:** From the pairwise knockdown data alone (no rescue construct needed): AKT1 alone (via siAKT2+3) sufficient in all 6 lines; AKT3 alone (via siAKT1+2) sufficient in all 6 lines; AKT2 alone (via siAKT1+3) sufficient in only 3 of 6 lines. This independently supports the "any one paralog can compensate" claim for AKT1 and AKT3, with a real caveat for AKT2 the paper's flat sentence doesn't convey.

**User:** "So if siAKT2+3 showed no effect in 1A how does that correlate with the expt in 1D?"

**Assistant:** Figure 1D uses A375 specifically. Figure 1A's siAKT2+3 (AKT1 alone) showed no effect in A375. Figure 1D's exogenous mouse-AKT1 rescue also prevents death in A375. Two independent methods (endogenous knockdown-pattern vs. exogenous rescue construct) agree, in the same cell line, that AKT1 alone is sufficient.

**User:** "Yes, so even one paralog in this cell line -- AKT2 -- can do what?"

**Assistant:** In A375 specifically, endogenous AKT2 alone (via siAKT1+3) sustains essentially normal proliferation — a second, independent line of support for the redundancy claim, this time for AKT2, in the one cell line where both experiments overlap.

**User:** [Synthesized:] "AKT1 and AKT3 are uniformly, unconditionally sufficient alone across every line -- yes this is a slight overreach or laziness in phrasing. Overall, it shows that if we choose the correct cell line we can show that one paralog is enough to sustain growth. Because this paralog's specific name... depends on the cell line, this fact... suggests that in melanoma one cannot a priori predict which isoform will take precedence... This is in keeping with the fact that in ALL melanoma lines it is necessary to knock down all 3 together."

**Assistant:** Captured this as a cross-row curator note on Row 2: which single paralog turns out to be sufficient is cell-line-dependent and unpredictable in advance from anything in this figure — which is the mechanistic rationale for why triple knockdown is the only strategy that works universally, not just an empirical observation that it does.

**User:** [Asked what "proliferation dropped" actually meant for siAKT1+3 — dropped to baseline, or partial?]

**Assistant:** Re-checked Panel A: in HT144, SK-MEL28, and MTG004, the siAKT1+3 trace rises well above the triple-knockdown baseline (~25-50% confluence vs. near-0%) — partial, not complete, compensation failure.

**User:** "So in Figure 1D what is plotted? And in Figure 1A what is plotted?"

**Assistant:** Figure 1A: Percent Confluence vs. Hours (proliferation), all 8 conditions, 6 cell lines. Figure 1D: Red Image Mean vs. Hours (Cytotox Red death-dye signal), only 4 conditions (staurosporine, siCtrl, triple knockdown, triple knockdown + WT Akt1), A375 only.

**User:** "So even in this cell line if siAKT2+3 showed no effect... what is the ultimate consequence with regards to tumor growth?" ... "Reduced growth -- not death at all for the AKT2 case. So in all cell lines AKT2 is sufficient to allow growth... whether it is 50% or 100% what does it mean clinically?"

**Assistant:** Clinically, any degree of continued growth (even reduced) means the tumor keeps expanding over time — not a controlled or regressing tumor. Reduced-but-nonzero growth under partial (AKT2-sparing) knockdown was never shown to translate to death in this figure; Panel D's death data exists only for the full triple knockdown. A partial-blockade strategy would therefore be cytostatic at best in some tumors and have no effect in others, with no way to predict which in advance.

**User:** [Corrected: "regardless of how much growth is reduced" was an overgeneralization not supported by the data — only the specific tested pairwise conditions showed no death, not all possible degrees of partial suppression.]

**Assistant:** Acknowledged and scoped the claim back to only what was directly tested.

**User:** "OK. The we have to frame the answer in that way. You have to block all 3 to significant levels to block growth sufficiently to get a good CLINICAL outcome."

**Assistant:** To get a clinically meaningful outcome, all three AKT paralogs must be silenced together, to a significant degree — partial coverage (even leaving just one paralog intact) permits continued tumor growth in some or all cases, which is not sufficient for disease control. Only complete, simultaneous loss of all three produced actual cell death and full growth arrest across every cell line tested.

**User:** "You were supposed to create a table of data for Figures 1A, 1D and the other ones you cited. Where is that?"

**Assistant:** Built `figure1_data_table.md` and a rendered `figure1_data_table.pdf` — four tables: Figure 1A's full proliferation grid (6 lines × 8 conditions), Figure 1D's cell-death data, the Figure 1B/C + Supplementary S3 verification-coverage matrix, and Supplementary S4's mouse-specificity control, plus a summary of the key gaps flagged during analysis.

---

*[Conversation continues from here into building a separate, fictionalized Project Planck benchmark prompt — using invented kinase/cell-line names rather than the real paper's data, per originality requirements. That work is documented separately in `project_planck_kinase_prompt.md` and `project_planck_fictionalized_table.md`, and is not included in this transcript since it is a derived, distinct deliverable rather than discussion of the paper itself.]*
